Figure 3.

DRrejTs display additive anti-ENKL activity over LMP2-rejTs in vivo

(A) Bioluminescence imaging of mice treated with LMP2-rejTs or DRrejTs. ENKL-bearing mice were divided into three groups that received no treatment (n = 5), LMP2-rejTs (n = 5), or DRrejTs (n = 5). No treatment indicates that mice were injected with ENKL cells but not treated with T cells. LMP2-rejTs or DRrejTs (5 × 10⁶ cells) were injected intraperitoneally once a week (three doses). Data represent at least two independent experiments. (B) Kaplan-Meier curve representing percentage survival of the experimental groups: no treatment, LMP2-rejTs, or DRrejTs. ∗p < 0.05, ∗∗p < 0.01 by log-rank test. ns, not significant. (C) Flow cytometric analysis of tetramer⁺/CD3⁺ population from peripheral blood of LMP2-rejT- or DRrejT-treated mice. Plots represent two independent experiments.